Longitudinal Trajectory Modeling to Assess Adherence to Sacubitril/Valsartan among Patients with Heart Failure

被引:0
作者
Mucherino, Sara [1 ]
Dima, Alexandra Lelia [2 ]
Coscioni, Enrico [3 ]
Vassallo, Maria Giovanna [3 ]
Orlando, Valentina [1 ]
Menditto, Enrica [1 ]
机构
[1] Univ Naples Federico II, Ctr Pharmacoecon & Drug Utilizat Res, Dept Pharm, CIRFF, I-80131 Naples, Italy
[2] Inst Recerca St Joan de Deu, Hlth Technol Assessment Primary Care & Mental Hlth, Santa Rosa 39-57, Esplugas de Llobregat 08950, Spain
[3] Azienda Osped Univ San Giovanni di Dio & Ruggi dAr, Div Cardiac Surg, I-84131 Salerno, Italy
关键词
medication adherence; heart failure; adherence trajectories; cluster analysis; ENALAPRIL; INFARCTION;
D O I
10.3390/pharmaceutics15112568
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Medication adherence in chronic conditions is a long-term process. Modeling longitudinal trajectories using routinely collected prescription data is a promising method for describing adherence patterns and identifying at-risk groups. The study aimed to characterize distinct long-term sacubitril/valsartan adherence trajectories and factors associated with them in patients with heart failure (HF). Subjects with incident HF starting sac/val in 2017-2018 were identified from the Campania Regional Database for Medication Consumption. We estimated patients' continuous medication availability (CMA9; R package AdhereR) during a 12-month period. We selected groups with similar CMA9 trajectories (Calinski-Harabasz criterion; R package kml). We performed multinomial regression analysis, assessing the relationship between demographic and clinical factors and adherence trajectory groups. The cohort included 4455 subjects, 70% male. Group-based trajectory modeling identified four distinct adherence trajectories: high adherence (42.6% of subjects; CMA mean 0.91 +/- 0.08), partial drop-off (19.6%; CMA 0.63 +/- 0.13), moderate adherence (19.3%; CMA 0.54 +/- 0.11), and low adherence (18.4%; CMA 0.17 +/- 0.12). Polypharmacy was associated with partial drop-off adherence (OR 1.194, 95%CI 1.175-1.214), while the occurrence of >= 1 HF hospitalization (OR 1.165, 95%CI 1.151-1.179) or other hospitalizations (OR 1.481, 95%CI 1.459-1.503) were associated with low adherence. This study found that tailoring patient education, providing support, and ongoing monitoring can boost adherence within different groups, potentially improving health outcomes.
引用
收藏
页数:13
相关论文
共 46 条
[1]   The k-means Algorithm: A Comprehensive Survey and Performance Evaluation [J].
Ahmed, Mohiuddin ;
Seraj, Raihan ;
Islam, Syed Mohammed Shamsul .
ELECTRONICS, 2020, 9 (08) :1-12
[2]   Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population [J].
Ajrouche, Aya ;
Estellat, Candice ;
De Rycke, Yann ;
Tubach, Florence .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (01) :37-46
[3]   Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries [J].
Bhatt, Ankeet S. ;
Vaduganathan, Muthiah ;
Solomon, Scott D. ;
Schneeweiss, Sebastian ;
Lauffenburger, Julie C. ;
Desai, Rishi J. .
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (09) :1506-1515
[4]   Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction [J].
Butler, Javed ;
Yang, Mei ;
Manzi, Massimiliano Alfonzo ;
Hess, Gregory P. ;
Patel, Mahesh J. ;
Rhodes, Thomas ;
Givertz, Michael M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (08) :935-944
[5]  
Cahill TJ, 2017, WORLD J CARDIOL, V9, P407, DOI 10.4330/wjc.v9.i5.407
[6]   Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction [J].
Carnicelli, Anthony P. ;
Li, Zhen ;
Greiner, Melissa A. ;
Lippmann, Steven J. ;
Greene, Stephen J. ;
Mentz, Robert J. ;
Hardy, N. Chantelle ;
Blumer, Vanessa ;
Shen, Xian ;
Yancy, Clyde W. ;
Peterson, Pamela N. ;
Allen, Larry A. ;
Fonarow, Gregg C. ;
O'Brien, Emily C. .
JACC-HEART FAILURE, 2021, 9 (12) :876-886
[7]   VALIDATION OF A COMBINED COMORBIDITY INDEX [J].
CHARLSON, M ;
SZATROWSKI, TP ;
PETERSON, J ;
GOLD, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) :1245-1251
[8]   Economic impact of medication non-adherence by disease groups: a systematic review [J].
Cutler, Rachelle Louise ;
Fernandez-Llimos, Fernando ;
Frommer, Michael ;
Benrimoj, Charlie ;
Garcia-Cardenas, Victoria .
BMJ OPEN, 2018, 8 (01)
[9]   Heart failure post-myocardial infarction: a review of the issues [J].
Dargie, H .
HEART, 2005, 91 :3-6
[10]   ESPACOMP Medication Adherence Reporting Guideline (EMERGE) [J].
De Geest, Sabina ;
Zullig, Leah L. ;
Dunbar-Jacob, Jacqueline ;
Helmy, Remon ;
Hughes, Dyfrig A. ;
Wilson, Ira B. ;
Vrijens, Bernard .
ANNALS OF INTERNAL MEDICINE, 2018, 169 (01) :30-+